TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35780318

Group type: EXPERIMENTAL
Intervention: PTW Advanced Markus chamber
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IBA PPC05 chamber
Number of subjects: 0

Group type: COMPARATOR
Intervention: Proton graphite calorimeter
Number of subjects: 0
Study: 32792317

Group type: COMPARATOR
Intervention: LDPRO
Number of subjects: 3

Group type: COMPARATOR
Intervention: HLPRO
Number of subjects: 3
Study: 34085999

Group type: EXPERIMENTAL
Intervention: Slow training group (SLDS e in 6 seconds)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Fast training group (SLDS e in 3 seconds)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both experimental groups (slow and fast training)
Number of subjects: 36
Study: 32473674

Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 0
Study: 35611518

Group type: EXPERIMENTAL
Intervention: Three times weekly heparin flushing
Number of subjects: 20

Group type: COMPARATOR
Intervention: Daily heparin flushing (standard of care)
Number of subjects: 20
Study: 34459774

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation and oxygen >30%
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV PC)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Caffeine administration
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Daily infusion volume
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Onset of enteral nutrition
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Hemoglobin levels on days 1, 3, and 7
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Leukocyte levels during the first 7 days of life
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Platelet count during the first 7 days of life
Number of subjects: 122
Study: 35764836

Group type: EXPERIMENTAL
Intervention: Quadratus lumborum block (QLB)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Caudal block
Number of subjects: 180

Group type: COMPARATOR
Intervention: TAP block
Number of subjects: 180
Study: 34559129

Group type: EXPERIMENTAL
Intervention: Zhen Wu Decoction (ZWD) with guideline directed medical therapies
Number of subjects: 0

Group type: COMPARATOR
Intervention: ZWD-granules simulations with guideline directed medical therapies
Number of subjects: 0
Study: 35413644

Group type: COMPARATOR
Intervention: Huangkui capsule (HKC) 2.5 g, TID
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Zicuiyin decoction (ZCY) crude drug amount 75 g, 150 ml, BID
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (HKC)
Number of subjects: 88
Study: 32964166

Group type: EXPERIMENTAL
Intervention: ICollab intervention for 6 months post-discharge
Number of subjects: 110

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 110
Study: 33155868

Group type: EXPERIMENTAL
Intervention: Sacubitril/Valsartan
Number of subjects: 0
Study: 32709230

Group type: EXPERIMENTAL
Intervention: Real-time monitoring and just-in-time SMS medication reminders
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Generic weekly SMS reminders
Number of subjects: 1000
Study: 35657298

Group type: EXPERIMENTAL
Intervention: m-health intervention integrating Theory of Planned Behavior (TPB) with tailored SMS and web-based knowledge, 8 weeks duration
Number of subjects: 194

Group type: COMPARATOR
Intervention: Web-based messages alone (control group)
Number of subjects: 194
Study: 33880645

Group type: EXPERIMENTAL
Intervention: Management of SAM by lady health workers (LHWs) at community level
Number of subjects: 829

Group type: COMPARATOR
Intervention: Standard CMAM program at health facility
Number of subjects: 829
Study: 32467417

Group type: EXPERIMENTAL
Intervention: GSK2862277 (26 mg nebulised dose)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: GSK2862277
Number of subjects: 33

Group type: COMPARATOR
Intervention: GSK2862277 and Placebo
Number of subjects: 33
Study: 34387353

Group type: COMPARATOR
Intervention: Low medical evidence
Number of subjects: 337

Group type: COMPARATOR
Intervention: Higher levels of reported pain severity
Number of subjects: 337
Study: 35735327

Group type: EXPERIMENTAL
Intervention: Theoretical guide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Audiovisual guide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group without study
Number of subjects: 0
Study: 32740347

Group type: EXPERIMENTAL
Intervention: Beta-blocker (BB)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitor (ACEi) and/or angiotensin II receptor blocker (ARB)
Number of subjects: 114
Study: 36442902

Group type: EXPERIMENTAL
Intervention: Home-based multidisciplinary interventions (intensive stage for 6 weeks and maintenance stage for 6 weeks) including health education, follow-up, behaviour guide, social support, skill training, coping with adverse drug reactions, and problem-solving.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ordinary care (control group)
Number of subjects: 0
Study: 34298035

Group type: EXPERIMENTAL
Intervention: IM trivalent inactivated influenza vaccine
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: imi+IM (IM vaccine after topical imiquimod)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: imi+ID (ID vaccine after topical imiquimod)
Number of subjects: 70
Study: 35845031

Group type: EXPERIMENTAL
Intervention: Aggressive lactated Ringer's (LR) infusion
Number of subjects: 136

Group type: COMPARATOR
Intervention: Aggressive normal saline (NS) infusion
Number of subjects: 136
Study: 33620419

Group type: EXPERIMENTAL
Intervention: GDC‐0334 (TRPA1 antagonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (placebo or no treatment not specified)
Number of subjects: 0
Study: 32072735

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg/day plus saxagliptin 5 mg/day plus metformin
Number of subjects: 82

Group type: COMPARATOR
Intervention: Glimepiride plus metformin
Number of subjects: 82
Study: 34515118

Group type: EXPERIMENTAL
Intervention: Personalized exercise programs delivered via smartphone (5 times/week for 6 weeks) including graded exercises for upper/lower body, flexibility, strength, and balance.
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Personalized exercise programs delivered via smartphone (5 times/week for 6 weeks).
Number of subjects: 52
Study: 32985249

Group type: EXPERIMENTAL
Intervention: Early coronary angiography
Number of subjects: 99
Study: 32493523

Group type: EXPERIMENTAL
Intervention: Standard evening meal (ST)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: High-carbohydrate evening meal (HC)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: High-protein evening meal (HP)
Number of subjects: 96
Study: 33865474

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 35742280

Group type: EXPERIMENTAL
Intervention: Square-stepping exercise (SSE) program, performed for 70 min per session, twice a week, for 12 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Square-stepping exercise (SSE) program
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 32869937

Group type: EXPERIMENTAL
Intervention: Same side conditioning contraction
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Crossover conditioning contraction
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control condition (no conditioning contraction)
Number of subjects: 107
Study: 36088952

Group type: EXPERIMENTAL
Intervention: Oral amoxicillin–clavulanic acid (75 mg/kg amoxicillin plus 18.75 mg/kg clavulanic acid, given daily in three doses for 7 days)
Number of subjects: 510

Group type: COMPARATOR
Intervention: Intravenous antibiotics (according to local protocol, for 7 days)
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Oral amoxicillin–clavulanic acid
Number of subjects: 510

Group type: COMPARATOR
Intervention: Intravenous antibiotics
Number of subjects: 510
Study: 34873188

Group type: EXPERIMENTAL
Intervention: Cost compensation (CC)
Number of subjects: 962

Group type: EXPERIMENTAL
Intervention: Decision aid (DA)
Number of subjects: 962

Group type: COMPARATOR
Intervention: Counselling as usual (Control)
Number of subjects: 962

Group type: COMPARATOR
Intervention: No cost compensation (Control)
Number of subjects: 962
Study: 33248603

Group type: COMPARATOR
Intervention: 0 mg/kg natural ASTA
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: 20 mg/kg natural ASTA
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: 40 mg/kg natural ASTA
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: 80 mg/kg natural ASTA
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: 160 mg/kg natural ASTA
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Storage at 4°C and 25°C
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Dietary ASTA level and storage time interaction
Number of subjects: 450
Study: 36418274

Group type: EXPERIMENTAL
Intervention: HPSD plus RA
Number of subjects: 60

Group type: COMPARATOR
Intervention: CPD plus RA
Number of subjects: 60
Study: 36226385

Group type: EXPERIMENTAL
Intervention: Education intervention (verbal explanation and demonstration of inhaler technique with metered-dose inhaler using a mannequin)
Number of subjects: 84
Study: 35675658

Group type: EXPERIMENTAL
Intervention: 8-Week Self-administered Home-Based Virtual Reality Program
Number of subjects: 0
Study: 32443695

Group type: EXPERIMENTAL
Intervention: Aronia melanocarpa juice (AMJ) treatment, 1.17 g/100 mL polyphenols
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: low‐polyphenol Aronia melanocarpa juice (dAMJ) treatment, 0.29 g/100 mL polyphenols
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 19
Study: 35034867

Group type: EXPERIMENTAL
Intervention: LUTS self-management booklet delivered by health care staff
Number of subjects: 1077

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1077
Study: 33736920

Group type: EXPERIMENTAL
Intervention: GC3110A (quadrivalent inactivated split-virion influenza vaccine)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control TIV (inactivated trivalent influenza vaccine)
Number of subjects: 200
Study: 33375942

Group type: EXPERIMENTAL
Intervention: Probiotic Vivomixx®
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 34963031

Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic training (3 times a week, including 5 min warm-up, 50 min aerobic dancing, and 5 min relaxation)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 106
Study: 32033935

Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) monotherapy
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA) monotherapy
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) monotherapy
Number of subjects: 4
Study: 33249268

Group type: EXPERIMENTAL
Intervention: Lidocaine 2%
Number of subjects: 80

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 80
Study: 32868680

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT) 2 times per week (G2x)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT) 3 times per week (G3x)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Detraining period
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Retraining period
Number of subjects: 40
Study: 32130742

Group type: EXPERIMENTAL
Intervention: Treatment 1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment 0
Number of subjects: 0
Study: 33052796

Group type: EXPERIMENTAL
Intervention: Sucrose octasulfate dressing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control dressing (neutral dressing)
Number of subjects: 0
Study: 35466057

Group type: EXPERIMENTAL
Intervention: Spherical silicone hydrogel
Number of subjects: 10

Group type: COMPARATOR
Intervention: Non-lens wear
Number of subjects: 10
Study: 34784577

Group type: EXPERIMENTAL
Intervention: Enzalutamide 160 mg plus androgen deprivation therapy (ADT)
Number of subjects: 1401

Group type: COMPARATOR
Intervention: Placebo plus androgen deprivation therapy (ADT)
Number of subjects: 1401
Study: 34759176

Group type: EXPERIMENTAL
Intervention: Difluprednate 0.05% nanoemulsion (DIFL) twice a day
Number of subjects: 259

Group type: COMPARATOR
Intervention: Prednisolone acetate 1% + phenylephrine hydrochloride 0.12% suspension (PRED) 4 times a day
Number of subjects: 259
Study: 33625363

Group type: EXPERIMENTAL
Intervention: Tailored mobile coaching (TMC) system
Number of subjects: 72
Study: 35488332

Group type: EXPERIMENTAL
Intervention: Multivariate analysis using partial least square-discriminate analysis (PLS-DA) with Mean Center preprocess method.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Univariate analysis.
Number of subjects: 30
Study: 34167458

Group type: EXPERIMENTAL
Intervention: SM at T4
Number of subjects: 82

Group type: COMPARATOR
Intervention: SM at T8
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo (light mechanical stimulus at T4)
Number of subjects: 82
Study: 35559733

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy (DBT)
Number of subjects: 72
Study: 33258534

Group type: EXPERIMENTAL
Intervention: Oral α-lipoic acid (ALA) 300 mg daily for 6 months + NB-UVB phototherapy
Number of subjects: 133

Group type: COMPARATOR
Intervention: Placebo + NB-UVB phototherapy
Number of subjects: 133
Study: 34370970

Group type: EXPERIMENTAL
Intervention: Tirzepatide 5 mg
Number of subjects: 1437

Group type: EXPERIMENTAL
Intervention: Tirzepatide 10 mg
Number of subjects: 1437

Group type: EXPERIMENTAL
Intervention: Tirzepatide 15 mg
Number of subjects: 1437

Group type: COMPARATOR
Intervention: Insulin degludec
Number of subjects: 1437
Study: 32047578

Group type: EXPERIMENTAL
Intervention: Remote Ischaemic Preconditioning (RIPC)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 56
Study: 35800230

Group type: EXPERIMENTAL
Intervention: Posterior lateral malleolus plate fixation
Number of subjects: 80

Group type: COMPARATOR
Intervention: Lateral malleolus plate fixation
Number of subjects: 80
Study: 33122081

Group type: EXPERIMENTAL
Intervention: Liability to Major Depressive Disorder (MDD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Liability to insomnia
Number of subjects: 0
Study: 36027238

Group type: EXPERIMENTAL
Intervention: Caffeinated drink (3 mg/kg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 33848764

Group type: EXPERIMENTAL
Intervention: Curettage and autogenous bone grafting (Group 1)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Curettage and bone graft substitutes (Group 2)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Curettage only (Group 3)
Number of subjects: 200
Study: 36418946

Group type: EXPERIMENTAL
Intervention: 3 ug/kg intranasal DEX plus 0.2 mg/Kg oral midazolam
Number of subjects: 156

Group type: COMPARATOR
Intervention: 2 ug/kg intranasal DEX plus 0.2 mg/Kg oral Midazolam
Number of subjects: 156
Study: 33420214

Group type: EXPERIMENTAL
Intervention: Subcutaneous and intraperitoneal analgesia
Number of subjects: 119

Group type: COMPARATOR
Intervention: Subcutaneous analgesia and intraperitoneal placebo
Number of subjects: 119

Group type: COMPARATOR
Intervention: Subcutaneous placebo and intraperitoneal analgesia
Number of subjects: 119

Group type: COMPARATOR
Intervention: Subcutaneous and intraperitoneal placebo
Number of subjects: 119
Study: 33580351

Group type: EXPERIMENTAL
Intervention: Expander with differential opening (EDO)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Fan-type expander (FE)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both EDO and FE
Number of subjects: 48
Study: 35396310

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion from 20:00 to 08:00 post-surgery
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion
Number of subjects: 348

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 348
Study: 33682262

Group type: EXPERIMENTAL
Intervention: Resistance exercise (REG)
Number of subjects: 107
Study: 33327266

Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis with alteplase combined with edaravone
Number of subjects: 118

Group type: COMPARATOR
Intervention: Intravenous thrombolysis of alteplase
Number of subjects: 118
Study: 35472628

Group type: EXPERIMENTAL
Intervention: Continuous IV epinephrine infusion (0.00375 mg/kg/min) with placebo IV normal saline (NS) boluses every 4 min
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Continuous placebo IV NS infusion with IV epinephrine boluses (0.015 mg/kg) every 4 min
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo IV NS for both infusion and boluses
Number of subjects: 45
Study: 34479759

Group type: EXPERIMENTAL
Intervention: Social norms nudges
Number of subjects: 6230

Group type: EXPERIMENTAL
Intervention: Reminding the impact on beneficiaries
Number of subjects: 6230

Group type: EXPERIMENTAL
Intervention: Defaults nudges (high vaccination intention)
Number of subjects: 6230
Study: 35575611

Group type: EXPERIMENTAL
Intervention: Vitamin C (500 mg/d)
Number of subjects: 14641

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14641

Group type: EXPERIMENTAL
Intervention: Vitamin E (400 IU every other day)
Number of subjects: 14641
Study: 34698461

Group type: EXPERIMENTAL
Intervention: Lingnan fire needling combined with 0.1% sodium hyaluronate eye drops
Number of subjects: 86

Group type: COMPARATOR
Intervention: 0.1% sodium hyaluronate eye drops
Number of subjects: 86
Study: 32329069

Group type: EXPERIMENTAL
Intervention: Epigenetic signature (11 epigenetic factors)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nomogram integrating epigenetic signature, pathological stage, and postoperative chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comprehensive signature
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: External validation series (combination of GSE17538, GSE33113, GSE37892)
Number of subjects: 0
Study: 35784723

Group type: EXPERIMENTAL
Intervention: Molnupiravir (800 mg) plus basic treatment for 5 days (BID)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (only basic treatment)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Molnupiravir (800 mg)
Number of subjects: 0
Study: 32493478

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) 400 mg orally daily for 3 days then 200 mg orally daily for an additional 11 days (total 14 days)
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Ascorbic acid 500 mg orally daily for 3 days then 250 mg orally daily for 11 days (total 14 days)
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Number of subjects: 2000
Study: 36032243

Group type: EXPERIMENTAL
Intervention: TRI 360TM capsules twice a day
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 32134163

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 2 mg/kg
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 10 mg/kg
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg
Number of subjects: 44
Study: 36321411

Group type: EXPERIMENTAL
Intervention: Active titration
Number of subjects: 172

Group type: COMPARATOR
Intervention: Usual titration
Number of subjects: 172
Study: 35918281

Group type: EXPERIMENTAL
Intervention: Videographic and plaque disclosing tablets (PDT)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Verbal instructions
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Plaque disclosing tablets (PDT)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Video group
Number of subjects: 96
Study: 35082248

Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation (MM)
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Hypnosis (HYP)
Number of subjects: 328

Group type: COMPARATOR
Intervention: Education (ED)
Number of subjects: 328
Study: 34653498

Group type: EXPERIMENTAL
Intervention: Dairy breakfast drinks varying in protein content and quantity
Number of subjects: 25
Study: 33044886

Group type: EXPERIMENTAL
Intervention: Plyometric training program (twice/week over three months plus traditional physical rehabilitation)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Traditional physical rehabilitation program (45 minutes/session, twice/week for three months)
Number of subjects: 34
Study: 35068726

Group type: EXPERIMENTAL
Intervention: Community-based intervention for tobacco cessation
Number of subjects: 200
Study: 33374471

Group type: EXPERIMENTAL
Intervention: GRSAPN (5 SNPs significantly associated with APN level)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GRSAll (47 SNPs from GWAS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GRSLimited (16 GRSAll-SNPs with p < 5.0 × 10−8)
Number of subjects: 0
Study: 35551149

Group type: EXPERIMENTAL
Intervention: Dolutegravir + Rilpivirine (early-switch group)
Number of subjects: 513

Group type: COMPARATOR
Intervention: CAR (control group)
Number of subjects: 513
Study: 33949942

Group type: EXPERIMENTAL
Intervention: Noninvasive peripheral nerve stimulation (NPNS)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 37
Study: 34072874

Group type: EXPERIMENTAL
Intervention: SNL-based RF model
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: WA-based RF model
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: FR-based RF model
Number of subjects: 155

Group type: COMPARATOR
Intervention: SVM models
Number of subjects: 155
Study: 33820778

Group type: EXPERIMENTAL
Intervention: anti-CD19 CAR T-cell therapy
Number of subjects: 71
Study: 36154278

Group type: EXPERIMENTAL
Intervention: Doxorubicin (6 cycles) and evofosfamide (11 cycles)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Trabectedin (24 cycles)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Pazopanib (14 months)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Gemcitabine monotherapy (5 months)
Number of subjects: 1
Study: 34189869

Group type: EXPERIMENTAL
Intervention: Atezolizumab + Bevacizumab (ATEZO/BEV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sorafenib (SOR)
Number of subjects: 0
Study: 32017005

Group type: EXPERIMENTAL
Intervention: VSL#3®
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: COMPARATOR
Intervention: VSL#3® vs Placebo
Number of subjects: 120
Study: 35322144

Group type: EXPERIMENTAL
Intervention: 8 g/day of gluten for 2 weeks; gluten-tolerating subjects received 16 g/day for 2 weeks and then 32 g/day for a further 2 weeks
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Low FODMAP strict gluten-free diet (GFD)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Gluten-containing diet
Number of subjects: 50